.Pharmacolibrary.Drugs.ATC.L.L04AA58 .Pharmacolibrary.Drugs.ATC.L.L04AA58| name: | EfgartigimodAlfa | |
| ATC code: | L04AA58 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 10 | mg |
| volume of distribution: | 15 | L |
| clearance: | 0.28 | L/h |
| other parameters in model implementation | ||
Efgartigimod alfa is a human IgG1-derived Fc fragment designed to bind to the neonatal Fc receptor (FcRn), resulting in a reduction of circulating IgG levels. It is approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive.
Pharmacokinetic parameters as reported in healthy adult subjects after intravenous infusion.
Jing, S, et al., & Pu, X (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants. Drugs in R&D 24(4) 505–515. DOI:10.1007/s40268-024-00490-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39368043